Jeffrey Tong, Ph.D., is a Partner at Third Rock Ventures and has more than 20 years of experience in building innovative biotechnology companies. Prior to Third Rock, he was Executive Chairman of Delinia (acquired by Celgene), President and CEO of Nora Therapeutics, a member of the founding executive team of Infinity Pharmaceuticals, and started his career at McKinsey & Company. In addition to the Terremoto board, Dr. Tong currently serves on the boards of Ambys Medicines,Asher Bio, Maze Therapeutics, and Septerna. Dr. Tong received his A.B., A.M., M.M.S., and Ph.D. from Harvard.